Table 3 Comparison of guideline dependent Active Surveillance eligibility of patients with PCa proven by combined MRI-targeted biopsy and systematic biopsy.

From: Active surveillance inclusion criteria under scrutiny in magnetic resonance imaging-guided prostate biopsy: a multicenter cohort study

Guideline

Type of biopsy

Number of patients

AS eligible patients (mean)

95% CI

p value

ESMO intermediate risk

systematic

1112

72.2

66.5–78.0

 

combined

1112

68.1

63.6–72.7

0.227

NICE intermediate risk

systematic

1112

72.2

66.5–77.9

 

combined

1112

68.1

63.6–72.6

0.226

AUA favourable intermediate risk

systematic

1112

58.1

52.0–64.3

 

combined

1112

50.3

46.3–54.3

0.093

NCCN favourable intermediate risk

systematic

584

50.7

42.3–59.2

 

combined

584

43.6

36.5–50.8

0.115

I+CS intermediate risk

systematic

584

44.2

35.4–52.9

 

combined

584

37.4

29.9–44.9

0.124

PCFA low risk

systematic

1112

29.9

23.7–36.0

 

combined

1112

18.4

16.6–20.1

0.018

EAU low risk

systematic

1112

22.3

16.3–28.3

 

combined

1112

15.1

11.7–18.5

0.078

NICE low risk

systematic

1112

22.1

16.1–28.1

 

combined

1112

15.0

11.5–18.5

0.079

NCCN low risk

systematic

1112

22.1

16.1–28.1

 

combined

1112

15.0

11.5–18.4

0.080

AUA low risk

systematic

1112

22.1

16.1–28.1

 

combined

1112

15.0

11.5–18.5

0.080

ESMO low risk

systematic

1112

22.1

16.0–28.1

 

combined

1112

15.0

11.6–18.4

0.080

KCE

systematic

1112

22.0

16.0–28.0

 

combined

1112

14.9

11.4–18.5

0.082

I+CS low risk

systematic

584

17.4

11.1–23.7

 

combined

584

10.6

6.7–14.6

0.073

DUA

systematic

583

14.7

8.7–20.6

 

combined

583

3.6

0.3–7.0

0.005

FCCG

systematic

583

14.6

8.7–20.6

 

combined

583

3.6

0.3–7.0

0.005

GSU

systematic

583

13.6

7.8–19.5

 

combined

583

3.5

0.2–6.8

0.007

CCO

systematic

583

13.6

7.7–19.5

 

combined

583

3.3

0.1–6.5

0.005

AUA very low risk

systematic

583

9.0

4.0–14.0

 

combined

583

5.2

1.5–8.9

0.167

NCCS

systematic

583

7.0

2.4–11.7

 

combined

583

1.7

0–4.2

0.053

NCCN very low risk

systematic

583

6.4

2.0–10.8

 

combined

583

1.7

0–4.2

0.073

  1. AUA American Urological Association [2], CCO Cancer Care Ontario [12], DUA Dutch Urological Association [13], EAU European Association of Urology [6], ESMO European Society for Medical Oncology [14], FCCG The Finnish Medical Society Duodecim [15], GSU German Society of Urology [5], I+CS Aragon Institute of Health Sciences [16], KCE Belgian Healthcare Knowledge Centre [17], NICE National Institute for Health and Clinical Excellence [8], NCCN The National Comprehensive Cancer Network [18], NCCS National Cancer Centre Singapore [19], PCFA Prostate Cancer Foundation of Australia [20].
Back to article page